Attached files

file filename
8-K - FORM 8-K - IMPERVA INCd581137d8k.htm

Exhibit 99.01

Imperva Announces Second Quarter 2013 Financial Results

 

   

Total revenue of $31.3 million during the second quarter, up 28% year-over-year

 

   

Second quarter services revenue growth of 49% was driven by the 156% year-over-year increase in subscription revenue

 

   

New customers increased 46% year-over-year to 185 during the second quarter

 

   

The number of deals valued over $100,000 up 36% year-over-year

 

   

Total deferred revenue at June 30, 2013 increased 32% year-over-year to $48.3 million

Redwood Shores, Calif. – August 7, 2013Imperva, Inc. (NYSE: IMPV), a pioneer and leader of a new category of business security solutions for critical applications and high-value data in the data center, today announced financial results for the second quarter ended June 30, 2013.

“The second quarter was highlighted by the 46% year-over-year growth in new customers and 36% increase in deals valued over $100,000,” stated Shlomo Kramer, President and Chief Executive Officer of Imperva. “While we continued to see strong demand for our fully integrated solution, performance in Europe and South America was impacted by sales execution challenges in these regions. Looking forward, we have already taken steps to reaccelerate growth and remain confident in our ability to grow global market share due to the continued strong pipeline of opportunities worldwide.”

Second Quarter 2013 Financial Highlights

 

   

Revenue: Total revenue for the second quarter of 2013 was $31.3 million, an increase of 28% compared to $24.6 million in the second quarter of 2012. Within total revenue, product revenue was $15.7 million compared to $14.0 million during the second quarter of 2012. Services revenue increased 49% year-over-year to $15.7 million and accounted for 50% of total revenue, up from 43% in the second quarter of 2012. Within services revenue, overall subscription revenue grew 156%, to $2.5 million, compared to the second quarter of 2012. Combined product and subscriptions revenue, a leading indicator of the strength of our business, was $18.2 million compared to $15.0 million during the second quarter of 2012.

 

   

Operating Profit (Loss): Operating loss as reported in accordance with U.S. generally accepted accounting principles (GAAP) was $(5.7) million for the second quarter compared to a loss of $(1.4) million during the second quarter in 2012. GAAP results included stock-based compensation expense of $3.6 million for the second quarter of 2013 and $1.2 million for the second quarter of 2012. Non-GAAP operating loss for the second quarter was $(2.1) million, compared to a loss of $(0.3) million during the same period in 2012, excluding the above mentioned charges.

 

   

Net Profit (Loss): GAAP net loss attributable to Imperva stockholders for the second quarter was $(5.9) million, or $(0.24) per share based on 24.2 million weighted average diluted shares outstanding. This compares to GAAP net loss attributable to Imperva stockholders of $(1.5) million, or $(0.07) per share based on 22.6 million weighted average shares outstanding in the prior-year period.


Non-GAAP net loss attributable to Imperva stockholders for the second quarter of 2013 was $(2.3) million, or $(0.10) per share based on 24.2 million weighted average diluted shares outstanding, excluding the above mentioned charges. This compares to non-GAAP net loss attributable to Imperva stockholders of $(0.4) million, or $(0.02) per share based on 22.6 million weighted average diluted shares outstanding in the prior-year period.

Both GAAP and non-GAAP profit and loss per share attributable to Imperva stockholders for the second quarter ended June 30, 2013 adjust for the loss attributable to Imperva’s non-controlling interest in Incapsula.

 

   

Balance Sheet: As of June 30, 2013, Imperva had cash, cash equivalents and investments of $110.4 million. Total deferred revenue of $48.3 million increased 32% compared to $36.5 million as of June 30, 2012.

Second Quarter and Recent Operating Highlights

 

   

During the second quarter of 2013, Imperva added 185 new customers, up 46% compared to the second quarter of last year. Imperva now has over 2,600 customers in more than 75 countries around the world.

 

   

During the second quarter of 2013, Imperva booked 76 deals with a value over $100,000, an increase of 36% compared to 56 deals in the second quarter of last year.

Business Outlook

The following forward-looking statements reflect expectations as of August 7, 2013. Results may be materially different and could be affected by the factors detailed in this press release and in recent Imperva SEC filings.

Third Quarter Expectations – Ending September 30, 2013

Imperva expects total revenue for the third quarter of 2013 to be in the range of $34.0 million to $35.0 million, representing growth in the range of 29% to 33% compared to the same period in 2012. The company expects in the third quarter of 2013 non-GAAP gross margins of approximately 80%. Further, Imperva expects in the third quarter of 2013 non-GAAP operating loss to be in the range of $(0.5) million to $(1.0) million and non-GAAP net loss attributable to Imperva stockholders to be in the range of $(1.0) million to $(1.5) million, or a loss of $(0.04) to $(0.06) per share, which excludes stock-based compensation expense.

Full Year Expectations – Ending December 31, 2013

Imperva expects total revenue for 2013 to be in the range of $135.0 million to $137.0 million, or up 30% to 31% compared to 2012. Imperva expects 2013 non-GAAP gross margins of approximately 80%. Further, the company expects 2013 non-GAAP operating loss to be in the range of $(1.5) million to $(2.5) million and non-GAAP net loss attributable to Imperva stockholders to be in the range of $(2.0) million to $(3.0) million, or a loss of $(0.06) to $(0.10) per share, which excludes stock-based compensation expense. Imperva expects capital expenditures for the full year to be in the range of $2.5 million to $3.5 million. Finally, the company expects to continue to generate positive cash flows from operations in 2013.


Quarterly Conference Call

Imperva will host a conference call today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to review the company’s financial results for the second quarter ended June 30, 2013. To access this call, dial 888.293.6960 for the U.S. and Canada or 719-457-2716 for international callers with conference ID #6020963. A live webcast of the conference call will be accessible from the investors page of Imperva’s website at www.imperva.com, and a recording will be archived and accessible at www.imperva.com. An audio replay of this conference call will also be available through August 21, 2013, by dialing 877.870.5176 for the U.S. and Canada, or 858.384.5517 for international callers and entering passcode #6020963.

Non-GAAP Financial Measures

Imperva reports all financial information required in accordance with U.S. generally accepted accounting principles (GAAP). To supplement the Imperva unaudited condensed consolidated financial statements presented in accordance with GAAP, Imperva uses certain non-GAAP measures of financial performance. The presentation of these non-GAAP financial measures is not intended to be considered in isolation from, as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP, and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the results of Imperva operations as determined in accordance with GAAP. The non-GAAP financial measures used by Imperva include historical non-GAAP net loss and non-GAAP basic and diluted loss per share. These non-GAAP financial measures exclude stock-based compensation from the Imperva unaudited condensed consolidated statement of operations.

For a description of these items, including the reasons why management adjusts for them, and reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures, please see the section of the accompanying tables titled “Use of Non-GAAP Financial Information” as well as the related tables that precede it. Imperva may consider whether other significant non-recurring items that arise in the future should also be excluded in calculating the non-GAAP financial measures it uses.

Imperva believes that these non-GAAP financial measures, when taken together with the corresponding GAAP financial measures, provide meaningful supplemental information regarding the performance of Imperva by excluding certain items that may not be indicative of the company’s core business, operating results or future outlook. Imperva management uses, and believes that investors benefit from referring to, these non-GAAP financial measures in assessing operating results of Imperva, as well as when planning, forecasting and analyzing future periods. These non-GAAP financial measures also facilitate comparisons of the performance of Imperva to prior periods.

Forward Looking Statements

This press release contains forward-looking statements, including without limitation those regarding Imperva’s “Business Outlook” (“Third Quarter Expectations – Ending September 30, 2013” and “Full Year Expectations – Ending December 31, 2013”); Imperva’s belief that the steps it has taken, including to address sales execution challenges in Europe and South America, will result in reacceleration of growth in these regions; and Imperva’s belief that the worldwide pipeline of opportunities will enable it to grow global market share. These forward-looking statements are subject to material risks and uncertainties that may cause actual results to differ substantially from expectations.


Investors should consider important risk factors, which include: the risk that demand for our business security solutions may not increase and may decrease; the risk that we may not timely introduce new products or versions of our products and that they may not be accepted by the market; the risk that competitors may be perceived by customers to be better positioned to help handle business security threats and protect their businesses from major risk; the risk that the growth of Imperva may be lower than anticipated; and other risks detailed under the caption “Risk Factors” in the company’s Form 10-Q filed with the Securities and Exchange Commission, or the SEC, on May 9, 2013 and the company’s other SEC filings. You can obtain copies of the company’s SEC filings on the SEC’s website at www.sec.gov.

The foregoing information represents the company’s outlook only as of the date of this press release, and Imperva undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, new developments or otherwise.

About Imperva

Imperva is a pioneer and leader of a new category of business security solutions for critical applications and high-value data in the data center. Imperva’s award-winning solutions protect against data theft, insider abuse, and fraud while streamlining regulatory compliance by monitoring and controlling data usage and business transactions across the data center, from storage in a database or on a file server to consumption through applications. With over 2,600 end-user customers in more than 75 countries and thousands of organizations protected through cloud-based deployments, securing your business with Imperva puts you in the company of the world’s leading organizations. For more information, visit www.imperva.com, follow us on Twitter or visit our blog.

© 2013 Imperva, Inc. All rights reserved. Imperva and the Imperva logo are trademarks of Imperva, Inc.

###


IMPERVA, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(On a GAAP basis)

(In thousands, except per share amounts)

(Unaudited)

 

     For the Three Months Ended     For the Six Months Ended  
     June 30,     June 30,     June 30,     June 30,  
     2013     2012     2013     2012  

Net revenue:

        

Products and license

   $ 15,671      $ 14,044      $ 29,825      $ 26,096   

Services

     15,668        10,510        30,099        19,976   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total net revenue

     31,339        24,554        59,924        46,072   

Cost of revenue(1):

        

Products and license

     2,446        2,274        4,322        4,128   

Services and support

     5,098        3,139        9,513        5,872   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total cost of revenue

     7,544        5,413        13,835        10,000   
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     23,795        19,141        46,089        36,072   

Operating expenses(1):

        

Research and development

     6,646        4,925        13,004        9,918   

Sales and marketing

     18,281        11,926        35,828        23,522   

General and administrative

     4,597        3,739        8,980        7,232   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     29,524        20,590        57,812        40,672   
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss from operations

     (5,729     (1,449     (11,723     (4,600

Other expense, net

     (55     11        (102     (59
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss before provision for income taxes

     (5,784     (1,438     (11,825     (4,659

Provision for income taxes

     261        227        415        380   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss

     (6,045     (1,665     (12,240     (5,039

Add: Loss attributable to noncontrolling interest

     130        132        266        235   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss attributable to Imperva, Inc. stockholders

   $ (5,915   $ (1,533   $ (11,974   $ (4,804
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss per share of common stock attributable to

        

Imperva, Inc. stockholders, basic and diluted

   $ (0.24   $ (0.07   $ (0.50   $ (0.21
  

 

 

   

 

 

   

 

 

   

 

 

 

Shares used in computing net loss per share of common stock, basic and diluted

     24,171        22,583        24,039        22,443   
  

 

 

   

 

 

   

 

 

   

 

 

 

(1)    Stock-based compensation expense as included in above:

        

Cost of revenue

   $ 255      $ 104      $ 468      $ 159   

Research and development

     720        260        1,386        387   

Sales and marketing

     1,643        439        2,976        700   

General and administrative

     974        363        1,615        588   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total stock-based compensation expense

   $ 3,592      $ 1,166      $ 6,445      $ 1,834   
  

 

 

   

 

 

   

 

 

   

 

 

 


IMPERVA, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

 

     As of     As of  
     June 30,     December 31,  
     2013     2012  

Assets

    

Current assets:

    

Cash and cash equivalents

   $ 70,021      $ 59,201   

Short-term investments

     40,362        43,126   

Restricted cash, current

     33        591   

Accounts receivable, net

     27,087        35,576   

Inventory

     368        328   

Deferred tax assets

     615        597   

Prepaid expenses and other current assets

     4,663        4,356   
  

 

 

   

 

 

 

Total current assets

     143,149        143,775   

Property and equipment, net

     5,448        5,515   

Severance pay fund

     3,535        3,150   

Restricted cash

     1,252        753   

Other assets

     772        764   
  

 

 

   

 

 

 

Total assets

   $ 154,156      $ 153,957   
  

 

 

   

 

 

 

Liabilities and stockholders’ equity

    

Current liabilities:

    

Accounts payable

   $ 3,773      $ 3,789   

Accrued compensation and benefits

     10,608        9,258   

Accrued and other current liabilities

     3,822        4,323   

Deferred revenue

     33,826        33,609   
  

 

 

   

 

 

 

Total current liabilities

     52,029        50,979   

Other liabilities

     2,349        2,638   

Deferred revenue

     14,477        12,682   

Accrued severance pay

     3,877        3,427   
  

 

 

   

 

 

 

Total liabilities

     72,732        69,726   

Stockholders’ equity:

    

Common stock

     2        2   

Additional paid-in capital

     167,764        157,989   

Accumulated deficit

     (85,491     (73,517

Accumulated other comprehensive income (loss)

     556        861   
  

 

 

   

 

 

 

Total Imperva, Inc. stockholders’ equity

     82,831        85,335   

Noncontrolling interest

     (1,407     (1,104
  

 

 

   

 

 

 

Total stockholders’ equity

     81,424        84,231   
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 154,156      $ 153,957   
  

 

 

   

 

 

 


IMPERVA, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

     For the Six Months Ended  
     June 30,     June 30,  
     2013     2012  

Cash flows from operating activities:

    

Net loss

   $ (12,240   $ (5,039

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

    

Depreciation and amortization

     1,269        850   

Stock-based compensation

     6,445        1,834   

Amortization of premiums/accretion of discounts on short-term investments

     383        197   

Changes in operating assets and liabilities:

    

Accounts receivable, net

     8,489        2,548   

Inventory

     (40     59   

Prepaid expenses and other assets

     (404     (793

Accounts payable

     (16     (1,114

Accrued compensation and benefits

     1,350        966   

Accrued and other liabilities

     (390     (496

Severance pay, net

     65        301   

Deferred revenue

     2,012        3,548   

Deferred tax assets

     (18     —     

Other

     (8     (4
  

 

 

   

 

 

 

Net cash provided by operating activities

     6,897        2,857   

Cash flows from investing activities:

    

Purchase of short-term investments

     (27,026     (41,256

Proceeds from sales/maturities of short-term investments

     29,361        2,310   

Net purchases of property and equipment

     (1,202     (885

Change in other assets

     —          (350

Change in restricted cash

     59        99   
  

 

 

   

 

 

 

Net cash provided by (used in) investing activities

     1,192        (40,082

Cash flows from financing activities:

    

Proceeds from issuance of common stock, net of repurchases

     2,893        1,087   
  

 

 

   

 

 

 

Net cash provided by financing activities

     2,893        1,087   

Effect of exchange rate changes on cash

     (162     (32
  

 

 

   

 

 

 

Net increase (decrease) in cash and cash equivalents

     10,820        (36,170

Cash and cash equivalents at beginning of period

   $ 59,201      $ 96,025   
  

 

 

   

 

 

 

Cash and cash equivalents at end of period

   $ 70,021      $ 59,855   
  

 

 

   

 

 

 


IMPERVA, INC. AND SUBSIDIARIES

(Reconciliation of GAAP to Non-GAAP Measures)

(In thousands, except per share amounts)

(Unaudited)

 

     For the Three Months Ended     For the Six Months Ended  
     June 30,     June 30,     June 30,     June 30,  
     2013     2012     2013     2012  

GAAP operating loss

   $ (5,729   $ (1,449   $ (11,723   $ (4,600

Plus:

        

Stock-based compensation expense

     3,592        1,166        6,445        1,834   
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP operating loss

   $ (2,137   $ (283   $ (5,278   $ (2,766
  

 

 

   

 

 

   

 

 

   

 

 

 

GAAP net loss attributable to Imperva, Inc. stockholders

   $ (5,915   $ (1,533   $ (11,974   $ (4,804

Plus:

        

Stock-based compensation expense

     3,592        1,166        6,445        1,834   
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP net loss

   $ (2,323   $ (367   $ (5,529   $ (2,970
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average shares outstanding, basic and diluted

     24,171        22,583        24,039        22,443   

Non-GAAP net loss, basic and diluted

   $ (0.10   $ (0.02   $ (0.23   $ (0.13


Use of Non-GAAP Financial Information

In addition to the reasons stated above, which are generally applicable to each of the items Imperva excludes from its non-GAAP financial measures, Imperva believes it is appropriate to exclude or give effect to certain items for the following reasons:

Stock-Based Compensation: When evaluating the performance of its consolidated results, Imperva does not consider stock-based compensation charges. Likewise, the Imperva management team excludes stock-based compensation expense from its operating plans. In contrast, the Imperva management team is held accountable for cash-based compensation and such amounts are included in its operating plans. Further, when considering the impact of equity award grants, Imperva places a greater emphasis on overall stockholder dilution rather than the accounting charges associated with such grants.

Imperva excludes stock based compensation charges from its non-GAAP financial measures primarily because they are non cash expenses that it does not consider part of ongoing operating results when assessing the performance of its business, and the exclusion of these expenses facilitates the comparison of results and business outlook for future periods with results for prior periods in order to better understand the long term performance of its business.

Investor Relations Contact Information

Seth Potter

646.277.1230

IR@imperva.com

Seth.Potter@icrinc.com